Bivalent SMAC Mimetics for Treating Cancer by Antagonizing Inhibitor of Apoptosis Proteins

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Inhibitors of Apoptosis Proteins (IAPs) promote cancer cell survival by inhibiting caspases and programmed cell death (apoptosis).
• Cancer cells exploit IAPs to resist apoptosis and therapeutic interventions.
• The second mitochondrial-derived activator of caspases (SMAC) protein antagonizes IAPs, presenting a therapeutic strategy.

Purpose of the Study:

• To review strategies for designing bivalent small-molecule SMAC mimetics.
• To discuss the progress in utilizing these mimetics to antagonize IAPs.
• To evaluate the clinical potential of bivalent SMAC mimetics in cancer therapy.

Main Methods:

• Focus on the design principles of bivalent small-molecule SMAC mimetics.
• Analysis of studies demonstrating SMAC mimetic efficacy against IAPs.
• Review of clinical trial data and preclinical findings.

Main Results:

• Small-molecule SMAC mimetics, particularly those based on the Ala-Val-Pro-Ile motif, are potent IAP antagonists.
• Bivalent SMAC mimetics, targeting BIR2 and BIR3 domains of XIAP, exhibit superior IAP antagonism compared to monovalent counterparts.
• Significant progress has been made in developing and applying these mimetics.

Conclusions:

• Bivalent SMAC mimetics represent a promising therapeutic avenue for overcoming apoptosis resistance in cancer.
• Further research into their design and clinical application is warranted.
• These compounds hold potential for improving cancer treatment outcomes.